Why do they bother to develop and test these drugs when it is well-established that the phytocannabinoids generated by the cannabis plant--especially THC and CBD--have unique and unequaled anti-Alzheimer's activities? It is quite clear that these cannabinoids work on several levels to protect the brain from changes that lead to various forms of dementia. THC and CBD work against inflammation and oxidation while neutralizing toxic compounds such as TNF--tumor necrosis factor and cannabinoids dissolve the beta-amyloid plaque while reducing the production of tau scar tissue and triggering the production of healthy replacement neurons. Big pharma just needs to acknowledge that nature does it better. Alzheimer’s Drug Failure: Implications for Future R&D in Neuroscience
Alzheimer’s disease is a debilitating neurodegenerative disease characterized by dementia and memory loss. It is the sixth leading cause of death in the United States, where more than 5 million people are affected. There is clearly a need for more effective therapies that address this and other neurodegenerative diseases; however, the research and development (R&D) efforts put forth by pharmaceutical companies have rarely been successful, as illustrated by the recent failure of the Alzheimer’s drug bapineuzumab in clinical trials.
Johnson & Johnson and Pfizer in separate press releases on August 6, 2012, announced the discontinuation of their joint Phase III clinical development of intravenous (IV) bapineuzumab in mild-to-moderate cases of Alzheimer’s disease. This comes on the heels of disappointing results from the clinical trial Study 301, in which bapineuzumab was being tested in patients who are non-carriers of the ApoE4 (Apolipoprotein E epsilon 4) gene. Results indicated that bapineuzumab did not satisfy either cognitive or functional performance endpoints. These disappointing study results follow similar results announced on July 23 from Study 302, in which bapineuzumab also failed to meet clinical endpoints in ApoE4 carrier patients.
Bapineuzumab IV is an antibody that targets the beta-amyloid protein (A), which is believed to cause brain toxicity and is implicated in the pathology of Alzheimer’s disease.